Skip to main content
SpringerLink
Log in

New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia

  • Conference proceedings
  • © 1990

Overview

Editors:
  1. W. Hiddemann

    1. Abteilung Innere Medizin A, Medizinische Klinik und Poliklinik, Münster, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. R. Mertelsmann

    1. Medizinische Klinik und Poliklinik Hämatologie — Onkologie, Klinikum der Albert-Ludwigs-Universität, Freiburg, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (7 papers)

  1. Front Matter

    Pages I-IX
    Download chapter PDF

  2. Aclarubicin in Single Agent and Combined Chemotherapy of Adult Acute Myeloid Leukemia

    • P. S. Mitrou
    Pages 1-7

  3. Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia

    • A. Lindemann, K. Kolbe, H. G. Fuhr, F. Rosenthal, G. Küsters, F. Herrmann et al.
    Pages 9-18

  4. Aclarubicin Plus Cytosine Arabinoside Versus Daunorubicin plus Cytosine Arabinoside in De Novo Acute Myelocytic Leukemia: A Danish National Trial

    • O. P. Hansen, J. Ellegaard, P. Bastrup-Madsen, H. Brincker, B. E. Christensen, S. Aa. Killmann et al.
    Pages 19-20

  5. Fractionated Aclacinomycin in Combination with Cytosine Arabinoside and Etoposide for Remission Induction in Adult Acute Myeloid Leukemia

    • D. Lutz, O. Krieger, H. Kasparu, E. Fiedler
    Pages 21-26

  6. Aclarubicin in the Treatment of Refractory Acute Leukemias

    • J. M. Rowe, A. Y. C. Chang, J. M. Bennett
    Pages 27-32

  7. Aclacinomycin A/Etoposide Combination Therapy for Advanced Relapsed Acute Myeloid Leukemia: Results of a Pilot Study of the Arbeitsgemeinschaft Internistische Onkologie

    • W. Hiddemann, K. Becker, A. Grote-Metke, R. Kuse, A. Bartholomäus, A. Reichle et al.
    Pages 33-40

  8. Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A Phase II Study

    • R. Schlag, B. Emmerich, J. Walther, T. Lipp, M. Hallek, E. Thiel
    Pages 41-50

  9. Back Matter

    Pages 51-52
    Download chapter PDF
Back to top

Keywords

About this book

Since the introduction of new anthracycline derivatives and anthrachi­ none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig­ nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys­ plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate­ dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable update on the current status of aclacinomycin A as used by experts in the treatment of he­ matologic malignancies.

Editors and Affiliations

  • Abteilung Innere Medizin A, Medizinische Klinik und Poliklinik, Münster, Germany

    W. Hiddemann

  • Medizinische Klinik und Poliklinik Hämatologie — Onkologie, Klinikum der Albert-Ludwigs-Universität, Freiburg, Germany

    R. Mertelsmann

Bibliographic Information

  • Book Title: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia

  • Editors: W. Hiddemann, R. Mertelsmann

  • DOI: https://doi.org/10.1007/978-3-642-75720-4

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1990

  • Softcover ISBN: 978-3-540-52613-1Published: 22 August 1990

  • eBook ISBN: 978-3-642-75720-4Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: IX, 52

  • Topics: Oncology, Hematology

  • Industry Sectors: Biotechnology, Health & Hospitals, Pharma

Publish with us

Policies and ethics

Back to top

Search

Navigation